As the overall epidemic has entered a low level of popularity, the price of pharmacies in many places in China has fallen.Among them, the prices of different specifications of Lianhuaqing Plague capsules/particles have fallen to 26 yuan (RMB, the same below, about S $ 5.08), which is significantly reduced from December 2022.Linghua Qing Plague producer Yiling Pharmaceutical's stock price has recently fallen.As of Tuesday (February 7) closed, Yiling Pharmaceutical closed at 29.15 yuan per share, with a total market value of 48.701 billion yuan, a decrease of 45.61%from the peak in December last year.
According to the Huaxia Times, the prices of Lianhua Qingjuan capsules/particles in different specifications of many chain pharmacies in Beijing have dropped to less than 26 yuan.In the early days of the epidemic prevention and control and optimization, a box of more than ten yuan Lianhua Qingjuan capsule was once fired to hundreds of yuan, and the price turned four or five times.There is a pharmacy Lianhuaqing Plague capsule 0.35g*48 capsules/box price of 54.9 yuan, and a pharmaceutical platform pushes a third -party e -commerce pharmacy (National Express) Lianhua Qingjuan Capsule 0.35g*48 capsule/box price is the price is101 yuan.
According to an online customer service, "the price reduction of the Lianhua Qing Plague appeared in mid -January, and the retrieval of the drug decreased significantly."
AlongThe price of "diving", the stock price of Yiling Pharmaceutical in the secondary market continued to fluctuate.On February 2, February 3, February 6, February 7, the stock price fell one after another.As of the close of February 7, Yiling Pharmaceutical closed at 29.15 yuan per share, with a total market value of 48.701 billion yuan.In the peak of Ling Pharmaceutical's stock price in December last year, the market value once exceeded 90 billion yuan.
In less than two months, the current stock price of Ling Pharmaceutical fell 45.61%from the high point in December 2022, and the market value also decreased by about 41.1 billion yuan.The company's actual controller Wu Yiling's personal net worth has also decreased from 28.4 billion yuan to 15.5 billion yuan, shrinking by about 13 billion yuan.
Reports pointed out that from the recent 2022 performance forecast released by Ling Pharmaceutical, the company is deliberately concealing the impact of the performance brought by the even flowers.
It is reported that the company's net profit attributable to shareholders of listed companies in 2022 was 2.15 billion yuan to 2.419 billion yuan, an increase of 60%to 80%year -on -year; net profit after deducting non -recurring gains and losses was 2.024 billion yuan until2.34 billion yuan, a year -on -year increase of 60%to 85%.It is learned that in the fourth quarter of 2022, the net profit of Yiling Pharmaceuticals was 736 million yuan to 1.05 billion yuan, an increase of 513%to 738%from the same period last year.
The rise of performance, expressed graceful expressions in Ling Pharmaceutical, and did not mention "sensitive words" such as Qinghua Qing Plague and a sharp rise.It is an announcement that the company's leading product sales revenue during the reporting period has increased a certain increase from the same period last year.
As of the first three quarters of 2022, the cold -cold products where the flowers of the Qingwan series are located have surpassed cardiovascular and cerebrovascular products, becoming the largest business sector in Yiling Pharmaceutical.
From 2013 to 2021, the company's net profit successfully achieved a "nine consecutive increase".Since 2022, Lianhua Qing Plague drugs have continued to make efforts. In the first three quarters, the company had achieved net profit of 1.414 billion yuan, exceeding 1.344 billion yuan last year.On October 28, the Secretary of Ling Pharmaceutical, Wu Rui, said at the performance briefing that in the first three quarters of this year, even the special product attributes of the new crown, flu, and a cold in the first three quarters of this year wereIt still achieves a year -on -year growth.
